Ahmed I, Majeed A, Powell R
Leicester Royal Infirmary, Infirmary Square, Leicester, UK.
Postgrad Med J. 2007 Sep;83(983):575-82. doi: 10.1136/pgmj.2007.059188.
Heparin-induced thrombocytopenia (HIT) is a potentially devastating immune mediated adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of heparin. Despite thrombocytopenia, bleeding is rare; rather, HIT is strongly associated with thromboembolic complications involving both the arterial and venous systems. A number of laboratory tests are available to confirm the diagnosis; however, when HIT is clinically suspected, treatment should not be withheld pending the result. Fortunately, therapeutic strategies have been refined, and new and effective therapeutic agents are available. Treatment options are focused on inhibiting thrombin formation or direct thrombin inhibition. Warfarin should not be used until the platelet count has recovered.
肝素诱导的血小板减少症(HIT)是一种潜在的、具有破坏性的免疫介导的药物不良反应,由在肝素存在下激活血小板的抗体出现所致。尽管存在血小板减少症,但出血情况罕见;相反,HIT与涉及动脉和静脉系统的血栓栓塞并发症密切相关。有多种实验室检查可用于确诊;然而,当临床上怀疑HIT时,不应等待结果而延误治疗。幸运的是,治疗策略已得到完善,并且有新的有效治疗药物可供使用。治疗选择集中在抑制凝血酶形成或直接抑制凝血酶。在血小板计数恢复之前不应使用华法林。